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Abstract
Background: Metabolic syndrome (MetS) is a major public health challenge. General practitioners
(GPs) could play a key role in its recognition. However, it often remains undiagnosed in primary
care. This study assesses how well GPs and patients recognise MetS among patients with coronary
heart disease or at least one of its risk factors.
Methods: Twenty-six health centres around Finland were randomly selected for the purpose of
identifying, over a two-week period in April 2005, patients meeting the inclusion criteria of
coronary heart disease or one of its risk factors. GPs and identified patients (n = 1880) were asked
to complete surveys that included a question about the patient's MetS status. A trained nurse
conducted health checks (n = 1180) of the identified patients, utilising criteria of MetS modified
from the National Cholesterol Program. Data from the GPs' survey were compared with those
from the health check to establish the extent of congruence of identification of MetS.
Results: Almost half (49.4%) of the patients met the criteria of MetS as established by objective
measures. However, in the GPs' survey responses, only 28.5% of the patients were identified as
having MetS. Additionally, these groups of MetS patients were not congruent. The sensitivity of the
GPs' diagnosis of MetS was 0.31 with a specificity of 0.73. Only 7.1% of the study patients stated
that they were suffering from MetS.
Conclusion: Detection of MetS is inaccurate among GPs in Finland. Most patients were not aware
of having MetS. The practical relevance of MetS in primary care should be reconsidered.
Background
Because of the epidemic of overweight and sedentary life-
style, the prevalence of metabolic syndrome (MetS) is
increasing worldwide [1], and the syndrome has become
a major public health challenge [2]. General practitioners
(GPs) play a key role in recognising MetS, but it is rarely
recorded as a diagnosis in clinical practice [3]. Despite sev-
eral efforts to make diagnosis feasible for clinicians, the
syndrome often remains undiagnosed in primary health
care [4].
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During the last decade, various medical organizations
have published their criteria of metabolic syndrome [5].
However, only the two most recent definitions are suita-
ble for the primary care framework. In 2001 the National
Cholesterol Education Program (NCEP) published a
working definition of the syndrome based on five com-
monly measured clinical criteria that physicians could
implement in their practices [6]. In 2005 the International
Diabetes Federation (IDF) released their set of criteria of
MetS [7]. The IDF definition provides a stepwise approach
to risk, with measurement of the waist as a simple initial
screening test followed by assessment of four other com-
ponents.
Finland has been a pioneer in promoting the concept of
MetS since the beginning of the nineties [8]. The leading
domestic professional journal for doctors in Finland first
published articles about this topic in 1992 [9]. MetS has
been represented in the Finnish Physician's Handbook
since 1996 [10]. The Handbook has portrayed MetS as a
risk factor of cardiovascular diseases and has described the
epidemiology and clinical features of MetS. The Finnish
version of ICD-10 has had a code for MetS (E66.00) since
1999. Moreover, since the early 2000s, there has been a
steady stream of information about MetS for GPs, pro-
vided mainly by specialists and pharmaceutical compa-
nies. Based on these efforts and scientific literature, MetS
can be considered to constitute a very common and
important risk factor of diabetes and cardiovascular dis-
eases. This means primary care physicians should have the
most important role in detecting and treating MetS. How-
ever, it remains unclear to what extent MetS is recognised
by GPs.
In this study we examined how well GPs recognise MetS
among patients with coronary heart disease (CHD) or at
least one of its risk factors (previously diagnosed diabetes
or metabolic syndrome, hypertension, smoking or dyslip-
idaemia). We compared these results with the actual per-
centage of patients meeting the criteria of MetS according
to modified NCEP criteria (Table 1). We also established
the extent to which the patients themselves were aware
that they had MetS.
Methods
Participants
The Heart 2005 study was carried out in 26 randomly
selected primary care health centres around Finland that
represented the entire Finnish public primary care system
in terms of size and location. Altogether 181 general prac-
titioners collected the data during two workweeks in April
2005. The study was a descriptive cross-sectional study,
and it was approved by the Ethics Committee of Kuopio
University Hospital and the University of Kuopio.
The patients included in the study had to have CHD or at
least one of its risk factors, such as previously diagnosed
diabetes or metabolic syndrome, hypertension, smoking
or dyslipidaemia. A patient was considered to have CHD
if it had been diagnosed by a doctor or it was indicated by
a specific code on the patient's health insurance card. The
study doctors made records of CHD and the risk factor sta-
tus of each patient. All the patients who visited the health
centre during the two weeks and met the study criteria
were registered and invited to attend a health check con-
ducted by a trained nurse.
From the regular patient stream, 1880 patients were iden-
tified as meeting the inclusion criteria of the study. Writ-
ten informed consent to participate in the study was given
by 1331 of them. Altogether 1208 filled in the patient
questionnaire and 1180 of them attended the health
check. Thus, the participation rate was 62.8%. The basic
characteristics and measurements of the study patients are
shown in Table 2.
The GPs collecting the patient data were mainly senior
doctors, and 67.5% of them had over 10 years of work
experience. The average age of female doctors was 42 years
and of male doctors, 47 years. There was a slight predom-
inance of female doctors (56.1%).
Data collection
At the health check, after a five-minute rest the nurse
measured the patient's blood pressure twice with an inter-
val of a few minutes, using a cuff fitting the patient's upper
arm circumference. The mean of the measurements was
used in analysing the results. The nurse recorded the latest
Table 1: Heart 2005 study criteria of metabolic syndrome according to modified National Cholesterol Education Program criteria.
Metabolic syndrome is present when three or more of the five criteria are met.
1. impaired glucose tolerance (IGT), increased fasting plasma glucose (IFG) or diabetes (DM)
2. hypertension ≥140/90 mmHg or medication for hypertension
3. serum triglyceride concentration ≥1.7 mmol/l
4. reduced serum HDL cholesterol < 1.2 mmol/l for women and < 1.0 mmol/l for men
5. waist circumference > 88 cm for women and > 102 cm for men.
HDL, high density lipoprotein.BMC Family Practice 2009, 10:76 http://www.biomedcentral.com/1471-2296/10/76
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laboratory results of haemoglobin, total serum choles-
terol, HDL and LDL cholesterol and triglycerides as well as
fasting plasma glucose and Hb-A1c values. If these tests
had not been conducted during the last 12 months, the
patient was sent to the laboratory. The nurse also meas-
ured the patient's height, weight and waist circumference.
The patients agreeing to take part in the study were asked
to fill in a questionnaire. One question asked whether the
patient had ever been diagnosed with or treated for meta-
bolic syndrome, with the possible answer being "yes" or
"no". The GPs filled in a doctor's questionnaire about
every patient registered for the study, and again one ques-
tion asked whether the patient had metabolic syndrome,
the answer being either "yes" or "no".
The criteria of metabolic syndrome used in the study were
given in the doctor's questionnaire (Table 1). The criteria
followed the NCEP definition [6], with some modifica-
tions. Impaired glucose tolerance and diabetes were
added to the first criterion. There was a higher threshold
value for hypertension and the use of antihypertensive
medication was included in the second criterion. Also, the
cut-off values were slightly lower for HDL cholesterol.
These modifications were made according to the criteria
of MetS in the Finnish Physician's Handbook 2004 [11].
The threshold value used for increased fasting plasma glu-
cose was ≥5.6 mmol/l.
The data collected in the patient's questionnaire, in the
doctor's questionnaire and at the health check were used
to analyse how many of the patients met the study criteria
of MetS. The laboratory results collected at the health
check were used to determine whether the patient met
each criterion according to the threshold values indicated
in Table 1. The patient was considered to have diabetes if
the question "Have you been diagnosed with diabetes?"
was answered positively or if the doctor had replied posi-
tively to the question whether or not the patient had dia-
betes. The patients were also asked "Have you undergone
an oral glucose tolerance test (OGTT)?" The possible
answers were (1) "no", (2) "yes, my blood glucose levels
were normal", and (3) "yes, my blood glucose levels were
above normal". The patient was considered to have IGT if
the third option was chosen.
Statistical analysis
The results are expressed as frequencies. The sensitivity
and specificity of the GPs' diagnosis of metabolic syn-
drome were calculated. All statistical analyses were per-
formed using SPSS statistical software for Windows,
version 16.0.
Results
The GPs had answered the question about metabolic syn-
drome in 1173 (99.4%) of the 1180 patient cases. They
assessed that 28.5% of the study patients (30.7% of the
men, 27.4% of the women) had MetS according to the
study criteria. However, 49.4% of the patients (50.8% of
the men, 49.6% of the women) met the study criteria of
metabolic syndrome according to the measurements and
records made at the nurse's appointment and the answers
from the patients' questionnaires. The measurements and
records were collected appropriately from 1160 (98.3%)
of the 1180 study patients, as 20 (1.7%) individuals had
to be excluded due to missing data. Moreover, the group
of patients with MetS according to the GPs' evaluation did
not quite match with the group of patients actually meet-
ing the study criteria of the syndrome. The sensitivity of
the general practitioners' diagnosis for MetS was 0.31 and
the specificity was 0.73 (Table 3).
Of the 1180 patients, 1059 (89.7%) had answered the
question about whether they had been diagnosed with or
treated for metabolic syndrome. In 75 (7.1%) cases the
answer was positive. Of the patients reporting having
MetS, 53 (70.7%) met the study criteria, as opposed to
466 subjects (48.2%) in the group reporting that they did
not have the syndrome.
Discussion
In our study, MetS was poorly detected by general practi-
tioners; the sensitivity of diagnosis was only 0.31. Much
work has been done during the last 15 years to familiarise
GPs with the syndrome, but it seems that it is still unrec-
ognised. On the other hand, the fact that only 75 (7.1%)
Table 2: Basic characteristics of 1160 Heart 2005 study subjects. 
Age (years) n = 1159 63.8 (11)
≥ 65 years (%) n = 1159 53.9
Sex (men %) n = 1135 42.8
BMI n = 1155 29.7 (5.1)
Current smokers (%) n = 1152 16.4
Hypertension (%) n = 1116 73.8
Dyslipidaemia (%) n = 1109 69.7
CHD (%) n = 1080 19.4
Diabetes (%) n = 1083 28.4
Fasting plasma glucose (mmol/l) n = 1042 6.15 (1.5)
SBP (mmHg) n = 1136 144 (19)
DBP (mmHg) n = 1135 84 (10)
Total cholesterol (mmol/l) n = 1085 5.11 (1.0)
Triglycerides (mmol/l) n = 1050 1.47 (0.80)
HDL cholesterol, men (mmol/l) n = 437 1.3 (0.38)
HDL cholesterol, women (mmol/l) n = 599 1.6 (0.47)
Waist circumference, men (cm) n = 465 105 (12)
Waist circumference, women (cm) n = 631 95 (14)
BMI, body mass index; CHD, coronary heart disease; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; HDL, high density 
lipoprotein.
Figures are means (SD) unless stated otherwise.BMC Family Practice 2009, 10:76 http://www.biomedcentral.com/1471-2296/10/76
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out of 1059 patients reported having MetS suggests that
the condition is even more unclear to patients.
It can be considered quite alarming that the GPs did not
recognise MetS in patients meeting the criteria of the syn-
drome. However, there may be valid reasons for this. For
example, over the years there have been several different
definitions of MetS, which may well have confused rather
than helped GPs in diagnosing the syndrome. We did not
use as strict a definition of MetS as actual NCEP criteria.
Further, some of the patients might have had IGT, result-
ing in more cases of MetS. Hence, the real proportion of
patients with MetS could have been slightly higher. How-
ever, the definition of MetS used in the present study is
comparable with the definition that was used in Finnish
primary care during the study period.
Our study was conducted during the hectic everyday rou-
tine in the primary care setting. This may have affected the
accuracy of MetS detection by the GPs. Nonetheless, these
are the real working conditions in a GP's office. MetS has
been promoted as a simple public health care strategy for
doctors to identify patients at high risk [12]. If it does not
work in real-life conditions, such as in the bustle of a GP's
office, then it will not meet its original aim.
There might be several reasons why GPs are not using the
diagnosis of MetS. Firstly, over the years more and more
counter-arguments have been raised about the diagnostic,
prognostic and therapeutic value of MetS [13-15]. Sec-
ondly, differing and even contradictory [15] statements
from various expert organizations have been announced.
On top of that, there are already several tools for identify-
ing apparently healthy individuals at an elevated risk of
diabetes, such as the glucose tolerance test [16,17] and the
diabetes risk score [18], or of CVD, such as the Framing-
ham risk score [19] or the SCORE model [20]. As the time
reserved for a GP's appointment is limited, it is not realis-
tic to assume that several risk assessment models would
be used in evaluating one patient.
How is MetS going to survive in this battle of prevention
strategies, and more importantly, what is the future role of
MetS? Metabolic syndrome is not likely to replace cur-
rently used global risk scoring algorithms, so both tradi-
tional risk factors and emerging metabolic markers
associated with metabolic syndrome should be incorpo-
rated in future risk assessment systems [21]. The need for
such global risk evaluation tools is emphasized even more
as waist circumference and waist-to-hip ratio have been
shown to be strongly associated with death [22]. In a busy
primary care clinical practice, this could mean a compu-
terized decision support system that would be integrated
into electronic patient records. This would enable the phy-
sician to make risk assessments based on a single algo-
rithm without any particular scoring systems.
A cohesive and clear message is urgently needed from the
scientific community to clarify how MetS and other risk
evaluation models should be used in primary care.
Conclusion
Detection of MetS is inaccurate among GPs in Finland.
Most patients were not aware of having MetS. The practi-
cal relevance of MetS in primary care should be reconsid-
ered.
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Table 3: Metabolic syndrome reported by general practitioners versus patients meeting the study criteria of metabolic syndrome in 
the Heart 2005 study (n = 1153).
MetS reported by GPs (n = 1173) (%)
Yes No
Patients meeting the study criteria of MetS (n = 1160) (%) yes 176 (30.9) 394 (69.1) 570
no 157 (26.9) 426 (73.1) 583
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